Suppr超能文献

[3H]-对氨基可乐定与人血小板质膜上α2-肾上腺素能受体状态及一个非肾上腺素能位点的结合。

Binding of [3H]-p-aminoclonidine to alpha 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes.

作者信息

Piletz J E, Andorn A C, Unnerstall J R, Halaris A

机构信息

Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio.

出版信息

Biochem Pharmacol. 1991 Jul 15;42(3):569-84. doi: 10.1016/0006-2952(91)90320-5.

Abstract

Characterization of the binding of [3H]p-aminoclonidine ([3H]PAC) to purified plasma membranes from human platelets has revealed multiple binding sites. [3H]PAC identified site-1 in the picomolar affinity range (site-1 KD estimates ranged from 13 to 94 pM). Site-1 displayed a rank order of competition by various compounds for [3H]PAC, indicative of an alpha 2-adrenoceptor, and was sensitive to 0.1 mM GTP. [3H]PAC also identified a second site with nanomolar affinity (site-2 KD estimates ranged from 0.7 to 1.7 nM). In the presence of 0.1 mM GTP, site-2 was not diminished significantly. Also in contrast to site-1, site-2 displayed low affinity for yohimbine (YOH), (-)-epinephrine and (-)-norepinephrine (NE). Therefore, site-2 could not be an active alpha 2-adrenoceptor; instead it had properties similar to a previously reported imidazoline-preferring binding site. A third site (site-3) bound [3H]PAC with a KD for site-3 of 26.6 +/- 10.0 nM (SD). Site-3 had a rank order of competition by various compounds for 5 nM [3H]yohimbine ([3H]YOH) binding which was indicative of an alpha 2-adrenoceptor. (-)-NE competed for 5 nM [3H]YOH binding at two sites: site-1 Ki = 32 pM, site-3 Ki = 239 nM. Treatment with 0.1 mM GTP completely removed site-1 and transferred the competitive binding of (-)-NE to low affinity (Ki = 437 nM). Thus, site-3 appears to be a free alpha 2-adrenoceptor. Bmax estimates for untreated membranes, derived from simultaneous multi-experiment curve-fitting analyses, were site-1 = 36 +/- 29 fmol/mg plasma membrane protein, site-2 = 95 +/- 34 fmol/mg and site-3 = 154 +/- 35 fmol/mg. We are the first to report a site for [3H]PAC binding on platelets (site-2) with properties uncharacteristic of an adrenoceptor. This observation appears to be due to our use of purified plasma membrane and low ionic strength buffer. These studies relate to reports of increased binding of [3H]PAC to platelets from depressed patients.

摘要

对[3H]对氨基可乐定([3H]PAC)与人血小板纯化质膜结合的特性研究揭示了多个结合位点。[3H]PAC在皮摩尔亲和力范围内鉴定出位点1(位点1的KD估计值范围为13至94 pM)。位点1显示出各种化合物对[3H]PAC的竞争排序,表明是α2 -肾上腺素能受体,并且对0.1 mM GTP敏感。[3H]PAC还鉴定出了一个具有纳摩尔亲和力的第二位点(位点2的KD估计值范围为0.7至1.7 nM)。在存在0.1 mM GTP的情况下,位点2没有明显减少。与位点1相比,位点2对育亨宾(YOH)、(-)-肾上腺素和(-)-去甲肾上腺素(NE)的亲和力较低。因此,位点2不可能是活性α2 -肾上腺素能受体;相反,它具有与先前报道的咪唑啉优先结合位点相似的特性。第三个位点(位点3)以26.6±10.0 nM(标准差)的KD结合[3H]PAC。位点3显示出各种化合物对5 nM [3H]育亨宾([3H]YOH)结合的竞争排序,表明是α2 -肾上腺素能受体。(-)-NE在两个位点竞争5 nM [3H]YOH结合:位点1的Ki = 32 pM,位点3的Ki = 239 nM。用0.1 mM GTP处理完全消除了位点1,并将(-)-NE的竞争性结合转移到低亲和力(Ki = 437 nM)。因此,位点3似乎是一个游离的α2 -肾上腺素能受体。通过同时进行的多实验曲线拟合分析得出的未处理膜的Bmax估计值为:位点1 = 36±29 fmol/mg质膜蛋白,位点2 = 95±34 fmol/mg,位点3 = 154±35 fmol/mg。我们首次报道了血小板上[3H]PAC的一个结合位点(位点2),其具有肾上腺素能受体不具备的特性。这一观察结果似乎是由于我们使用了纯化的质膜和低离子强度缓冲液。这些研究与抑郁症患者血小板上[3H]PAC结合增加的报道相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验